Table 1 Demographics and baseline disease characteristics according to week-36 concordance category
|  | Week 36 (n = 763) | ||
|---|---|---|---|
Positive discordance (n = 189) | Concordance (n = 556) | Negative discordance (n = 18) | |
Age, years, mean (SD) | 48.8 (11.5) | 47.9 (12.1) | 49.8 (10.8) |
Female, n (%) | 160 (84.7) | 455 (81.8) | 17 (94.4) |
White, n (%) | 130 (68.8) | 424 (76.3) | 14 (77.8) |
Prior alcohol, n (%) | 22 (11.6) | 64 (11.5) | 2 (11.1) |
Prior tobacco, n (%) | 39 (20.6) | 98 (17.6) | 4 (22.2) |
Rheumatoid factor+, n (%) | 130 (68.8) | 411 (73.9) | 11 (61.1) |
Duration of disease symptoms, years, mean (SD) | 6.8 (6.9) | 6.9 (6.9) | 9.0 (8.1) |
Weekly dose of methotrexate, mg, mean (SD) | 16.4 (2.4) | 16.5 (2.8) | 15.8 (1.9) |
Prior treatment, n (%) | Â | Â | Â |
Methotrexate | 189 (100.0) | 556 (100.0) | 18 (100.0) |
DMARDs other than methotrexate | 46 (24.3) | 145 (26.1) | 8 (44.4) |
Glucocorticoids | 117 (61.9) | 325 (58.5) | 10 (55.6) |
NSAIDs | 133 (70.4) | 422 (75.9) | 14 (77.8) |